Welcome to our dedicated page for Chromadex news (Ticker: CDXC), a resource for investors and traders seeking the latest updates and insights on Chromadex stock.
ChromaDex Corp. (NASDAQ: CDXC), transitioning to the name Niagen Bioscience, Inc. with a new Nasdaq ticker symbol NAGE, generates a steady flow of news centered on NAD+ science and healthy aging. As the self-described global authority on nicotinamide adenine dinucleotide (NAD+), the company regularly issues updates on its Niagen ingredient, Tru Niagen supplement brand, and pharmaceutical-grade Niagen IV and injection products.
News for CDXC often includes financial results and outlooks, where ChromaDex reports quarterly and annual net sales, gross margins, net income, and cash flow metrics, along with commentary on trends in Tru Niagen and Niagen ingredient sales. These releases may also discuss expectations for future revenue growth, margin performance, and planned investments in research, development, and marketing.
Investors can also expect corporate and investor relations announcements, such as participation in healthcare and growth company conferences, investor summits, and panel discussions on longevity and supplementation. These events typically feature company management presenting ChromaDex’s strategy, financial performance, and updates on its NAD+ research and product pipeline.
Another key category of news involves product and partnership developments. ChromaDex has announced the expansion of Niagen IV and related pharmaceutical-grade Niagen products across wellness clinic networks, as well as collaborations where Niagen serves as a hero ingredient in third‑party longevity supplements. The company also highlights recognition in industry lists and awards related to health products and business impact.
Finally, ChromaDex issues scientific and regulatory updates, including information about FDA designations for nicotinamide riboside in rare disease indications and progress toward regulatory milestones. For anyone tracking CDXC, or its successor symbol NAGE, this news feed offers a consolidated view of the company’s financial performance, clinical and regulatory progress, commercial expansion, and branding evolution around Niagen and NAD+ science.
ChromaDex Corp. (NASDAQ:CDXC) has partnered with Juvenis to launch its Tru Niagen® supplement in South Korea. Tru Niagen®, a leading Vitamin B3 product, aims to boost NAD+ levels and is recognized for its health benefits. With South Korea projected to see a 23% increase in its elderly population by 2050, the partnership seeks to meet growing demands for health supplements. The product will be available on major platforms including NaverSmartStore and Gmarket. ChromaDex continues to lead research in NAD+ supplementation.
ChromaDex Corp. (NASDAQ:CDXC) will present virtually at the 12th Annual Invitational on June 8, at 4:30 p.m. ET. The event will feature over 200 companies, and ChromaDex's CEO Rob Fried and CFO Kevin Farr will lead the presentation. Additionally, the management team will hold one-on-one meetings with institutional investors throughout the day. Interested parties can find more information and the webcast link on the LD Micro website. ChromaDex is focused on healthy aging and is known for its NAD+ precursor, Niagen®.
ChromaDex Corp. (NASDAQ:CDXC) has announced the establishment of a joint venture, ChromaDex Asia, aimed at distributing its product, Tru Niagen®, in mainland China. The new venture includes partners Crystal Lake Developments, Pioneer Idea Holdings, and Hong Kong Taikuk. Successful commercialization hinges on approval from China's State Administration for Market Regulation, which is critical for health food registration. CEO Rob Fried emphasized this move as a significant milestone in the company’s strategy for the Chinese market, with the JV's formation contingent upon customary closing conditions.
ChromaDex Corp. (NASDAQ:CDXC) reported first-quarter 2022 net sales of $17.3 million, marking an 18% increase year-over-year, primarily driven by a 20% rise in Tru Niagen® sales to $14.9 million. The gross margin decreased to 61.0% from 62.9% due to changes in business mix and increased supply chain costs. Operating expenses rose to $18.3 million, resulting in a net loss of $7.7 million or $(0.11) per share. For 2022, the company anticipates 15-20% revenue growth, with ongoing investment in brand awareness and R&D, despite potential COVID-19 headwinds.
ChromaDex Corp. (NASDAQ:CDXC) will hold a conference call on May 12, 2022, at 4:30 p.m. ET to discuss its first-quarter financial results for the period ending March 31, 2022. The company intends to release these results shortly after market close on the same day. Interested participants should dial in 10 minutes early. A live broadcast and replay of the call will be available on the company's website. ChromaDex specializes in bioscience, focusing on NAD+ research and its flagship product, Niagen.
ChromaDex Corp. (NASDAQ: CDXC) has appointed two new Board members: Kristin Patrick, Chief Marketing Officer of Claire's Inc., and Ann Cohen, CFO of The Institute of Internal Auditors. Patrick has extensive experience in brand strategy from companies like PepsiCo and Playboy, while Cohen brings significant financial expertise from Taylor Morrison Homes and Starwood Vacation Ownership. The company expresses gratitude to departing Board members Jeff Baxter and Caroline Levy, and notes that Kurt Gustafson and Steve Block will not seek re-election at the upcoming annual meeting in June 2022.
ChromaDex (NASDAQ:CDXC) has launched Tru Niagen® Immune, a unique immune health supplement designed to enhance NAD+ levels, vital for aging cells. This product contains a proprietary blend of NAD-boosting Niagen®, vitamins C, D, zinc, and Theracurmin®. NAD+ levels can deplete by up to 80% under immune stress, making this product essential for immune cell function. Retailing at $37.50 for a 30-count bottle, Tru Niagen Immune is now available in the U.S., meeting the growing demand for comprehensive immune support.
ChromaDex Corp. (NASDAQ:CDXC) has been granted a continuation patent, U.S. Patent No. 11,274,117, enhancing its intellectual property for nicotinamide riboside (NR) and other NAD precursors. This patent supports the manufacturing process of NR chloride and new salt forms, crucial for future innovations. With this addition, ChromaDex holds over 40 patents related to Niagen®, its leading product in the healthy aging sector. Both patents expire on November 10, 2037, indicating a strong competitive position in the expanding NAD market.
FAQ
What is the current stock price of Chromadex (CDXC)?
What is the market cap of Chromadex (CDXC)?
